Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application

被引:0
|
作者
Lasch, Anna [1 ]
Schweikert, Timo [2 ]
Dora, Eva [1 ]
Kolb, Theresa [3 ]
Schurig, Hanne Lilian [3 ,5 ]
Walther, Andreas [4 ]
机构
[1] Tech Univ Dresden, Biopsychol, Dresden, Germany
[2] Justus Liebig Univ Giessen, Psychotherapie & Systemneurowissensch, Giessen, Germany
[3] Univ klinikum Carl Gustav Carus Dresden, Div Psychol & Social Med & Dev Neurosci, Dresden, Germany
[4] Univ Zurich Psychol Inst, Klin Psychol Psychotherapie, Zurich, Switzerland
[5] Univ klinikum Carl Gustav Carus Dresden, Psychosoziale Med & Entwicklungsneurowissensch, D-01307 Dresden, Germany
关键词
Psilocybin; therapy; depression; neurobiology; 5-HT-2A receptor; terminal diseases; MYSTICAL-TYPE EXPERIENCES; LIFE-THREATENING CANCER; MODE NETWORK ACTIVITY; FUNCTIONAL CONNECTIVITY; PSYCHEDELIC DRUGS; BRAIN; SEROTONIN; PSYCHOTHERAPY; AMYGDALA; MODULATION;
D O I
10.1055/a-2046-5202
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Successful therapy of mental disorders is very important in view of the high level of suffering of those affected. Since established pharmaceutical and psychotherapeutic approaches do not lead to the desired improvement in all cases, complementary or alternative treatment methods are intensively researched. Psilocybin-assisted psychotherapy seems particularly promising, and has been approved in the USA for larger clinical trials. Psilocybin belongs to the group of psychedelics and influences psychological experiences. In assisted therapy, psilocybin is administered in controlled doses under medical supervision to patients with different mental disorders. In the studies conducted so far, longer-term positive effects could be shown after just one or a few doses. In order to provide a better understanding of the potential therapeutic mechanisms, this article will first describe neurobiological and psychological effects of psilocybin. To better assess the potential of psilocybin-assisted psychotherapy for various disorders, clinical studies conducted so far with patients administered psilocybin are reviewed.
引用
收藏
页码:230 / 245
页数:16
相关论文
共 50 条
  • [41] Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder A Randomized Clinical Trial
    Bogenschutz, Michael P.
    Ross, Stephen
    Bhatt, Snehal
    Baron, Tara
    Forcehimes, Alyssa A.
    Laska, Eugene
    Mennenga, Sarah E.
    O'Donnell, Kelley
    Owens, Lindsey T.
    Podrebarac, Samantha
    Rotrosen, John
    Tonigan, J. Scott
    Worth, Lindsay
    JAMA PSYCHIATRY, 2022, 79 (10) : 953 - 962
  • [42] Impact of parental history of substance use disorders on the clinical course of anxiety disorders
    Maria E Pagano
    Richard Rende
    Benjamin F Rodriguez
    Eric L Hargraves
    Amanda T Moskowitz
    Martin B Keller
    Substance Abuse Treatment, Prevention, and Policy, 2
  • [43] Impact of parental history of substance use disorders on the clinical course of anxiety disorders
    Pagano, Maria E.
    Rende, Richard
    Rodriguez, Benjamin F.
    Hargraves, Eric L.
    Moskowitz, Amanda T.
    Keller, Martin B.
    SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2007, 2
  • [44] Treatment of Comorbid Substance Use and Anxiety Disorders A Case Study
    Ries, Richard
    Wolitzky-Taylor, Kate B.
    Operskalski, Joachim T.
    Craske, Michelle G.
    Roy-Byrne, Peter
    JOURNAL OF ADDICTION MEDICINE, 2011, 5 (04) : 248 - 253
  • [45] Substance Use Disorders and Anxiety: A Treatment Challenge for Social Workers
    Brady, Kathleen T.
    Haynes, Louise F.
    Hartwell, Karen J.
    Killeen, Therese K.
    SOCIAL WORK IN PUBLIC HEALTH, 2013, 28 (3-4) : 407 - 423
  • [46] Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance
    Morissette, Audrey
    Ouellet-Plamondon, Clairelaine
    Jutras-Aswad, Didier
    SANTE MENTALE AU QUEBEC, 2014, 39 (02): : 21 - 37
  • [47] Early Life Stress as a Risk Factor for Substance Use Disorders: Clinical and Neurobiological Substrates
    Varghese, Sajoy P.
    Dong, Montalvo-Ortiz J. L. H.
    Csernansky, J. G. Eiger
    Koola, R. I.
    Sajoy, M. M.
    Varghese, P.
    BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 69S - 69S
  • [48] Early Life Stress as a Risk Factor for Substance use Disorders: Clinical and Neurobiological Substrates
    Varghese, Sajoy Purathumuriyil
    Montalvo-Ortiz, Janitza L.
    Csernansky, John G.
    Eiger, Rodney, I
    Herrold, Amy A.
    Koola, Maju Mathew
    Dong, Hongxin
    INDIAN JOURNAL OF PSYCHOLOGICAL MEDICINE, 2015, 37 (01) : 36 - 41
  • [49] Depression and substance use disorders: Clinical comorbidity and shared neurobiology
    Calarco, Cali A.
    Lobo, Mary Kay
    NEUROBIOLOGY OF ADDICTION AND CO-MORBID DISORDERS, 2021, 157 : 245 - 309
  • [50] Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice
    Olfson, M
    Shea, S
    Feder, A
    Fuentes, M
    Nomura, Y
    Gameroff, M
    Weissman, MM
    ARCHIVES OF FAMILY MEDICINE, 2000, 9 (09) : 876 - 883